Biz-Dev Execs From GBS Consults LLC Say Emerging Medtech Companies Can Get Strategics’ Attention Before They Are “De-Risked”

What do acquirers want to see in a start-up before buying?

Recently, the 50th IN3 (Investment in Innovation) conference produced by Elsevier Business Intelligence offered a rich opportunity for early-stage medtech companies not only to present their respective businesses but also to hear directly from their key customers - investors and business development executives - about how they approach investments and acquisitions in this space.

Click here to download a complimentary copy of a summary of the IN3 conference panel session: “What Acquirers Want to See in a Start-Up Before Buying”, authored by Gerry Seery, President and Founder of GBS Consults LLC. Before founding GBS Consults, Mr. Seery was Senior Vice President, Global Sales & Marketing, at CryoLife Inc. (NYSE: CRY).

Mr. Seery’s summary focuses on an IN3 panel discussion, “What Do Acquirers Want to See in a Start-Up Before Buying?”, led by moderator David Cassak, Vice President Content, Elsevier Business Intelligence, the panelists included: Mano Chinnaswamy Vice President Business Development (DePuy Synthes, JNJ); Thomas Umbel, SVP, Business Development (Hologic, Inc.); and Shon Steger, Director Business Development (Biomet). They reviewed a range of issues and considerations which they face in evaluating candidate companies. These three execs represent franchises that have a combined $15 billion in annual revenues.

GBS Consults LLC (www.gbsconsults.com, ph: 404-312-8611, gbseery@gbsconsults.com) based in Marietta, Georgia, works with start-up and emerging companies to optimize business performance and create brand and value. We help our clients execute transformation—including new organizational and business models to drive their business forward.